Best Practices in Contemporary Diagnostic Immunohistochemistry: Panel Approach to Hematolymphoid Proliferations

Abstract

Context.—The complexities of diagnostic hematopathology in the modern era are well known, and even in this molecular era, immunophenotypic studies, together with routine histopathology, remain a critical component in the evaluation of many lymphoid proliferations. With numerous antibodies that can be used on routinely fixed, paraffin-embedded tissue sections, immunohistochemistry has become increasingly valuable. It then becomes a challenge knowing the best approach to the selection of antibodies to use and how to interpret them. Objective.—To present a pragmatic immunohistochemical approach to the evaluation of lymphoid proliferations that stresses the utility of 2 limited panels to deal with the most commonly encountered lymphomas. Data Sources.—English-language literature published between 1990 and 2008. Conclusions.—A relatively limited panel of immunohistochemical stains may be used to diagnose and subclassify many of the more common lymphomas, although some cases will require additional stains and others fewer, depending on the case complexity. Immunohistochemical stains must always be interpreted in the context of the histopathologic and other ancillary studies.

Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non‐Hodgkin lymphoma

“…Promising efficiency has also been reported in other CD30-positive NHL including cutaneous T-cell lymphoma (CTCL) subtypes such as cutaneous anaplastic T-cell lymphoma and transformed mycosis fungoide (MF) (Prince et al, 2017), as well as CD30-positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (Horwitz et al, 2019). Detecting CD30 in lymph nodes biopsy usually relies on immunohistochemistry (IHC) (Garcia & Swerdlow, 2009), which is performed in histopathology laboratories and considered as the gold standard until now. IHC is based on positive cell counting, however its sensitivity in distinguishing between positive and negative cells is variable (Wilkins, 2011).…”

T-Cell Lymphoma: Clinical Presentation and Therapeutic Outcome from a Tertiary Care Hospital in Eastern India

“…Lymph node excision biopsy was planned and conducted in our surgery department, and the histopathological examination (HPE) and immunohistochemical (IHC) assessment were done [4][5][6]. Patients with skin lesions were subjected to skin biopsy in the department of dermatology, followed by histopathological and immunohistochemical (IHC) assessment [7]. Subsequently, we did staging investigations by contrast enhanced computed tomography (CECT) of the neck, thorax, abdomen and pelvis in all patients.…”

“…On the basis of the lymph node histology and size and nuclear characteristics of the lymphocytes, further immunohistochemistry panels were applied. The diagnosis of T-NHL was confirmed by using IHC markers such as CD45, CD5, CD7, CD3, CD2 and CD1a [7].…”

Perbedaan Antara Ekspresi Cd3, Cd20, Cd43 Limfoma Non-Hodgkin Sel B Dan Lesi Limfoproliferatif Reaktif

“…2,9,10 Imunohistokimia dapat menentukan galur diferensiasi sel limfoid, mengidentifikasi maturasi dan fungsi sel limfoid, mengetahui tipe klonalitas, serta respons terhadap kemoterapi. 10,11,12 Penelitian ini bertujuan untuk mengetahui apakah terdapat perbedaan ekspresi CD3, CD20, CD43 di antara lesi limfoproliferatif jinak dan ganas.…”

“…2,14,15 Imunohistokimia secara teknis dapat di-lakukan pada laboratorium diagnostik patologi secara luas dan efisien karena menggunakan blok parafin dari pemeriksaan histopatologi sebelumnya, sehingga tidak membutuhkan pengambilan jaringan ber-ulang. 10,11,12 Imunohistokimia pada penelitian ini dilakukan menggunakan panel antibodi CD3, CD20, CD43. Ketiga antibodi ini dipilih untuk membedakan karakter jinak atau ganas dari lesi limfoproliferatif reaktif dan limfoma non-Hodgkin sel B. CD3 merupakan penanda sel limfosit T yang memiliki sensitivitas dan spesifitas baik.…”